<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="71458"><DrugName>DEX-M74</DrugName><DrugSynonyms><Name><Value>hereditary inclusion body myopathy therapy, National Human Genome Research Institute/ New Zealand Pharmaceuticals</Value></Name><Name><Value>ManNAc, National Human Genome Research Institute/ New Zealand Pharmaceuticals</Value></Name><Name><Value>N-Acetyl-D-mannosamine, National Human Genome Research Institute/ New Zealand Pharmaceuticals</Value></Name><Name><Value>DEX-M74</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ManNAc</Value></Name><Name><Value>N-acetyl-D-mannosamine (GNE myophathy), Leadiant Biosciences</Value></Name></DrugSynonyms><CompanyOriginator id="1041848">National Human Genome Research Institute</CompanyOriginator><CompaniesPrimary><Company id="1111676">Escala Therapeutics Inc</Company><Company id="1041848">National Human Genome Research Institute</Company><Company id="20518">National Institutes of Health</Company><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Company id="19946">Leadiant Biosciences Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="17054">New Zealand Pharmaceuticals Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1041848" type="Company"><TargetEntity id="5016900854" type="organizationId">National Human Genome Research Institute</TargetEntity></SourceEntity><SourceEntity id="1111676" type="Company"><TargetEntity id="5046434880" type="organizationId">Escala Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="17054" type="Company"><TargetEntity id="4296057555" type="organizationId">New Zealand Pharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="19946" type="Company"><TargetEntity id="4297326430" type="organizationId">Leadiant Biosciences Inc</TargetEntity></SourceEntity><SourceEntity id="20518" type="Company"><TargetEntity id="5001347606" type="organizationId">National Institutes of Health</TargetEntity></SourceEntity><SourceEntity id="3084" type="ciIndication"><TargetEntity id="10067757" type="MEDDRA"></TargetEntity><TargetEntity id="D005923" type="MeSH"></TargetEntity><TargetEntity id="-898159958" type="omicsDisease"></TargetEntity><TargetEntity id="5317" type="siCondition"></TargetEntity><TargetEntity id="1542" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3441" type="ciIndication"><TargetEntity id="10018372" type="MEDDRA"></TargetEntity><TargetEntity id="D015433" type="MeSH"></TargetEntity><TargetEntity id="-1005518329" type="omicsDisease"></TargetEntity><TargetEntity id="3085" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="672" type="ciIndication"><TargetEntity id="10028641" type="MEDDRA"></TargetEntity><TargetEntity id="D009135" type="MeSH"></TargetEntity><TargetEntity id="136" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="3084">Focal segmental glomerulosclerosis</Indication><Indication id="3410">Minimal change disease</Indication><Indication id="3441">Membranous glomerulonephritis</Indication><Indication id="672">Myopathy</Indication></IndicationsPrimary><ActionsPrimary><Action id="52819">N acetylmannosamine kinase stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="1408">Muscle system agent</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-12-03T05:13:06.000Z</LastModificationDate><ChangeDateLast>2018-11-07T00:00:00.000Z</ChangeDateLast><AddedDate>2011-05-20T12:08:23.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="20518" linkType="Company"&gt;NIH&lt;/ulink&gt; affiliates &lt;ulink linkID="1041848" linkType="Company"&gt;National Human Genome Research Institute&lt;/ulink&gt; (NHGRI) and &lt;ulink linkID="1072251" linkType="Company"&gt;Therapeutics for Rare and Neglected Diseases&lt;/ulink&gt;, in  collaboration with sublicensee &lt;ulink linkID="1111676" linkType="Company"&gt;Escala Therapeutics&lt;/ulink&gt; (formerly Altamira Bio; under license from &lt;ulink linkID="17054" linkType="Company"&gt;New Zealand Pharmaceuticals&lt;/ulink&gt;) are developing   N-acetyl-D-mannosamine, DEX-M74 (ManNAc; structure shown), a precursor of sialic acid, for the potential oral treatment of hereditary inclusion body myopathy (HIBM), minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS) and membranous nephropathy (MN) [&lt;ulink linkID="1724628" linkType="Reference"&gt;1724628&lt;/ulink&gt;], [&lt;ulink linkID="1193093" linkType="Reference"&gt;1193093&lt;/ulink&gt;], [&lt;ulink linkID="1308837" linkType="Reference"&gt;1308837&lt;/ulink&gt;], [&lt;ulink linkID="1326316" linkType="Reference"&gt;1326316&lt;/ulink&gt;], [&lt;ulink linkID="1365130" linkType="Reference"&gt;1365130&lt;/ulink&gt;],  [&lt;ulink linkID="1629723" linkType="Reference"&gt;1629723&lt;/ulink&gt;], [&lt;ulink linkID="1678418" linkType="Reference"&gt;1678418&lt;/ulink&gt;], [&lt;ulink linkID="1696308" linkType="Reference"&gt;1696308&lt;/ulink&gt;];  NHGRI and licensee  &lt;ulink linkID="19946" linkType="Company"&gt;Leadiant Biosciences&lt;/ulink&gt; are also developing the drug for the potential treatment of GNE myopathy [&lt;ulink linkID="2063700" linkType="Reference"&gt;2063700&lt;/ulink&gt;], [&lt;ulink linkID="2063800" linkType="Reference"&gt;2063800&lt;/ulink&gt;]. In September 2018, Leadiant Biosciences reported the program was in phase IIb/III stage [&lt;ulink linkID="2086577" linkType="Reference"&gt;2086577&lt;/ulink&gt;]. In December 2015, a phase I study for MCD, FSGS and MN was initiated in the US. At that time, the study was expected to complete in January 2018 [&lt;ulink linkID="1724628" linkType="Reference"&gt;1724628&lt;/ulink&gt;]. In March 2008, NHGRI was seeking to outlicense the drug through NIH Office Of Technology Transfer [&lt;ulink linkID="1432316" linkType="Reference"&gt;1432316&lt;/ulink&gt;]; in March 2013, this was still the case [&lt;ulink linkID="1395222" linkType="Reference"&gt;1395222&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In February 2016, the EMA's COMP recommended granting N-acetyl-D-mannosamine monohydrate Orphan designation for the treatment of GNE myopathy [&lt;ulink linkID="1738218" linkType="Reference"&gt;1738218&lt;/ulink&gt;]; in March 2016, the Orphan designation was granted [&lt;ulink linkID="1749169" linkType="Reference"&gt;1749169&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In October 2018, clinical data from NEPTUNE Consortium were presented at the 2018 ASN Kidney Week in San Diego, CA. Across all three disease entities (minimal change disease patients, FSGS and membranous nephropathy patients), hyposialylation was detected in an unexpectedly high percentage of human kidney biopsies. A trend of correlation of severe glomerular hyposialylation with reduced eGFR, increased interstitial fibrosis and tubular atrophy was observed in particular in FSGS patients [&lt;ulink linkID="2085162" linkType="Reference"&gt;2085162&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2018,  Leadiant Biosciences reported the program was in phase IIb/III stage [&lt;ulink linkID="2086577" linkType="Reference"&gt;2086577&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2017, a randomized, double-blinded, placebo-controlled trial in patients (expected n = 50) with GNE myopathy was planned to initiate to evaluate the efficacy and safety of ManNAc  [&lt;ulink linkID="2063700" linkType="Reference"&gt;2063700&lt;/ulink&gt;]; in August 2018, this was still the case [&lt;ulink linkID="2063800" linkType="Reference"&gt;2063800&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2012, a phase I/II trial was planned as a follow up to the initial study and that patients would receive multiple doses of DEX-M74. Further, a phase II study was to be initiated to determine the clinical effectiveness of DEX-M74 after the successful completion of the phase I/II trial [&lt;ulink linkID="1326151" linkType="Reference"&gt;1326151&lt;/ulink&gt;]; in September 2014, development was ongoing [&lt;ulink linkID="1589499" linkType="Reference"&gt;1589499&lt;/ulink&gt;]. In January 2015, an open label, non-randomized, single group assignment, pharmacokinetics, pharmacodynamics, phase I/II trial (&lt;ulink linkID="220612" linkType="Protocol"&gt;NCT02346461&lt;/ulink&gt;; 150068, 15-HG-0068) was initiated in the US, in patients (expected n = 30) with GNE myopathy, to assess the safety of DEX-M74. At that time, the trial was expected to complete in November 2015 [&lt;ulink linkID="1629723" linkType="Reference"&gt;1629723&lt;/ulink&gt;]. In September 2017, clinical data were presented at 13th ICIEM in Rio de Janeiro, Brazil. A sustained increase in plasma free sialic acid levels was reported with bid ManNAc treatment, while there was no accumulation in plasma. Muscle biopsies showed improvement in membrane sialylation at three months relative to baseline after the administration of ManNAc [&lt;ulink linkID="1966159" linkType="Reference"&gt;1966159&lt;/ulink&gt;]. In August 2018, the trial was completed [&lt;ulink linkID="1629723" linkType="Reference"&gt;1629723&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2015, an open-label, parallel assignment, tolerability, non-randomized, multiple ascending dose, safety, tolerability, pharmacokinetics, phase I study (&lt;ulink linkID="249423" linkType="Protocol"&gt;NCT02639260&lt;/ulink&gt;; 160036, 16-DK-0036) was initiated in the US, in children and adults (expected n = 12) with MCD, FSGS and MN. At that time, the study was expected to complete in January 2018 [&lt;ulink linkID="1724628" linkType="Reference"&gt;1724628&lt;/ulink&gt;].  In October 2018, it was reported at the 2018 ASN Kidney Week in San Diego, CA that preliminary results were found to be promising regarding safety and tolerability of ManNAc [&lt;ulink linkID="2085162" linkType="Reference"&gt;2085162&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, a clinical trial was planned for early 2012 at the NIH Clinical Center [&lt;ulink linkID="1193093" linkType="Reference"&gt;1193093&lt;/ulink&gt;]. In July 2012, an IND application for the phase I study was expected to be filed with the FDA  later that month and the phase I study was expected to begin within the following months [&lt;ulink linkID="1308149" linkType="Reference"&gt;1308149&lt;/ulink&gt;], [&lt;ulink linkID="1308659" linkType="Reference"&gt;1308659&lt;/ulink&gt;]. By September 2012 an IND had been approved by the US FDA and a randomized, placebo-controlled, double-blind, escalating single-dose, phase I safety/tolerability trial (&lt;ulink linkID="92540" linkType="Protocol"&gt;NCT01634750&lt;/ulink&gt;; 120207; 12-HG-0207) was initiated in the US to evaluate oral DEX-M74 in HIBM  patients  (n = 18). The trial was expected to be completed in February 2013 [&lt;ulink linkID="1326316" linkType="Reference"&gt;1326316&lt;/ulink&gt;], [&lt;ulink linkID="1326151" linkType="Reference"&gt;1326151&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2011, a natural, observational, prospective history study (NCT01417533; 110218; 11-HG-0218) was initiated in patients (n = 100) with HIBM in the US; in August 2012, the trial was ongoing [&lt;ulink linkID="1326322" linkType="Reference"&gt;1326322&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2018, preclinical data were presented at the 2018 ASN Kidney Week in San Diego, CA. In three nephrotic mouse models (Gne-deficient, neuraminidase-induced nephropathy and adriamycin-induced nephropathy mouse models), po ManNAc therapy ameliorated neonatal lethality, podocyte effacement and glomerular hyposialylation and proteinuria [&lt;ulink linkID="2085162" linkType="Reference"&gt;2085162&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By September 2012, data had demonstrated that DEX-M74 was effective in controlling sialic acid levels in a mouse model with a specific GNE mutation. By that time, toxicology studies have been completed [&lt;ulink linkID="1326151" linkType="Reference"&gt;1326151&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2012, the drug had been found to increase sialylation in kidney tissue and limb muscles in mice [&lt;ulink linkID="1308149" linkType="Reference"&gt;1308149&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By May 2011, animal model studies indicated that the compound delayed or halted HIBM progression. At that time, the organizations were collaborating to complete preclinical development activities required for the FDA to review an IND application [&lt;ulink linkID="1193093" linkType="Reference"&gt;1193093&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19946">Leadiant Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-09-28T00:00:00.000Z</StatusDate><Source id="2086577" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1041848">National Human Genome Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-26T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111676">Escala Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-07-17T00:00:00.000Z</StatusDate><Source id="1678418" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3441">Membranous glomerulonephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-23T00:00:00.000Z</StatusDate><Source id="1724628" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3084">Focal segmental glomerulosclerosis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-23T00:00:00.000Z</StatusDate><Source id="1724628" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3410">Minimal change disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-23T00:00:00.000Z</StatusDate><Source id="1724628" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072251">Therapeutics for Rare and Neglected Diseases</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-02-01T00:00:00.000Z</StatusDate><Source id="1365130" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111676">Escala Therapeutics Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-02-16T00:00:00.000Z</StatusDate><Source id="1738218" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-03-28T00:00:00.000Z</StatusDate><Source id="1432316" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17054">New Zealand Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-07-17T00:00:00.000Z</StatusDate><Source id="1678418" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1041848">National Human Genome Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-06-30T00:00:00.000Z</StatusDate><Source id="1326151" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17054">New Zealand Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-05-19T00:00:00.000Z</StatusDate><Source id="1193093" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041848">National Human Genome Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-07-31T00:00:00.000Z</StatusDate><Source id="1326322" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17054">New Zealand Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-07-31T00:00:00.000Z</StatusDate><Source id="1326322" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041848">National Human Genome Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-24T00:00:00.000Z</StatusDate><Source id="1326151" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17054">New Zealand Pharmaceuticals Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-09-24T00:00:00.000Z</StatusDate><Source id="1326151" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19946">Leadiant Biosciences Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="672">Myopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-08-15T00:00:00.000Z</StatusDate><Source id="2063700" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1111676">Escala Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="672">Myopathy</Indication><AwardedIndication>Treatment of GNE myopathy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-21T00:00:00.000Z</MileStoneDate><Source id="1749169" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1111676">Escala Therapeutics Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="672">Myopathy</Indication><AwardedIndication>Treatment of GNE myopathy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-02-18T00:00:00.000Z</MileStoneDate><Source id="1738218" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1111676">Escala Therapeutics Inc</OwnerCompany><Country id="US">US</Country><Indication id="672">Myopathy</Indication><AwardedIndication>Treatment of hereditary inclusion body myopathy type 2</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-04-05T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-09529"><Name>N acetylmannosamine kinase</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2085162" linkType="reference" linkID="2085162"&gt;2085162&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1032809">Fortress Biotech Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1141701">Leadiant Biosciences Spa</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17054">New Zealand Pharmaceuticals Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="24839">Harvard Medical School</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="15">Drug - CRADA</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CC(=O)N[C@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O</Smiles></StructureSmiles><Deals><Deal id="134994" title="New Zealand Pharmaceuticals and NHGRI to develop DEX-M74 for HIBM "></Deal><Deal id="155414" title="Altamira Bio to develop New Zealand Pharmaceuticals' ManNAc for HIBM   "></Deal><Deal id="249123" title="NHGRI and Leadiant enter into a CRADA to develop ManNAc for GNE myopathy"></Deal><Deal id="249126" title="NIH to award funding to Brigham to evaluate ManNAc for GNE myopathy"></Deal></Deals><PatentFamilies><PatentFamily id="1613664" number="WO-2008150477" title="N-acetyl mannosamine as a therapeutic agent"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="New Zealand Pharmaceuticals Ltd" id="17054"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>